Price to Book Value (P/BV)
since 2005
Calculation
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | 2.67 | = | 716.72 | ÷ | 268.50 | 268.50 | = | 29,353,600 | ÷ | 109,324,682 | |
| Feb 5, 2024 | 3.96 | = | 936.33 | ÷ | 236.63 | 236.63 | = | 25,973,100 | ÷ | 109,761,896 | |
| Feb 6, 2023 | 3.77 | = | 780.86 | ÷ | 207.31 | 207.31 | = | 22,664,000 | ÷ | 109,325,532 | |
| Feb 7, 2022 | 3.60 | = | 622.36 | ÷ | 172.92 | 172.92 | = | 18,768,800 | ÷ | 108,539,282 | |
| Feb 8, 2021 | 4.81 | = | 494.90 | ÷ | 102.91 | 102.91 | = | 11,025,300 | ÷ | 107,131,899 | |
| Feb 7, 2020 | 3.79 | = | 381.87 | ÷ | 100.80 | 100.80 | = | 11,089,700 | ÷ | 110,019,809 | |
| Feb 7, 2019 | 5.07 | = | 406.46 | ÷ | 80.14 | 80.14 | = | 8,757,300 | ÷ | 109,277,189 | |
| Feb 8, 2018 | 5.66 | = | 322.62 | ÷ | 57.05 | 57.05 | = | 6,144,078 | ÷ | 107,696,798 | |
| Feb 9, 2017 | 8.58 | = | 360.00 | ÷ | 41.94 | 41.94 | = | 4,449,245 | ÷ | 106,080,755 | |
| Feb 11, 2016 | 10.53 | = | 367.24 | ÷ | 34.88 | 34.88 | = | 3,654,837 | ÷ | 104,788,145 | |
| Feb 12, 2015 | 16.22 | = | 401.74 | ÷ | 24.77 | 24.77 | = | 2,542,325 | ÷ | 102,616,962 | |
| Feb 13, 2014 | 16.74 | = | 326.98 | ÷ | 19.53 | 19.53 | = | 1,952,076 | ÷ | 99,928,368 | |
| Feb 15, 2013 | 12.91 | = | 164.93 | ÷ | 12.78 | 12.78 | = | 1,245,385 | ÷ | 97,450,601 | |
| Feb 21, 2012 | 19.19 | = | 99.26 | ÷ | 5.17 | 5.17 | = | 485,732 | ÷ | 93,888,977 | |
| Feb 17, 2011 | 6.42 | = | 37.67 | ÷ | 5.87 | 5.87 | = | 527,815 | ÷ | 89,959,044 | |
| Feb 18, 2010 | 5.49 | = | 26.66 | ÷ | 4.86 | 4.86 | = | 396,762 | ÷ | 81,653,378 | |
| Feb 26, 2009 | 2.94 | = | 15.40 | ÷ | 5.24 | 5.24 | = | 418,852 | ÷ | 79,976,762 | |
| Feb 27, 2008 | 3.24 | = | 18.90 | ÷ | 5.83 | 5.83 | = | 460,267 | ÷ | 78,984,745 | |
| Mar 12, 2007 | 5.77 | = | 19.04 | ÷ | 3.30 | 3.30 | = | 216,624 | ÷ | 65,630,744 | |
| Feb 28, 2006 | 8.16 | = | 16.37 | ÷ | 2.01 | 2.01 | = | 114,002 | ÷ | 56,858,721 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
- Share Price Trend
- The share price exhibited fluctuations during the earlier years, initially rising from $16.37 in 2006 to $37.67 in 2011, followed by a significant surge reaching a peak of $494.9 in 2021. Post-2021, the share price continued an upward trajectory, hitting a high of $936.33 in 2024 before experiencing a decline to $716.72 in 2025. This overall growth suggests a substantial increase in market valuation over the observed period, despite some volatility in recent years.
- Book Value per Share (BVPS) Dynamics
- BVPS increased consistently, moving from $2.01 in 2006 to $268.5 in 2025. The growth in BVPS accelerated notably from 2013 onwards, indicating steady accumulation of shareholders’ equity or retained earnings relative to share count. This steady upward trend portrays a strengthening financial foundation and suggests enhanced intrinsic value of the company over the years.
- Price-to-Book Value Ratio (P/BV) Analysis
- The P/B ratio demonstrated considerable variability, initially decreasing from 8.16 in 2006 to a low of 2.67 in 2025. Notably, the ratio spiked substantially between 2011 and 2013, reaching a peak of 19.19 in 2012, which corresponds with surging share prices outpacing the growth in book value. Following this spike, the ratio steadily declined, indicating that market price growth began to align more closely with the increase in tangible book value, suggesting a moderation in market overvaluation or an improved alignment with intrinsic company value in recent years.
- Overall Financial Insights
- The data reveals a strong upward trajectory in both share price and book value per share over the long term, reflecting growth in both market perception and fundamental equity. The P/B ratio’s peak during 2012 suggests a period of heightened investor speculation or market optimism, which normalized in subsequent years. The recent decrease in share price coupled with rising BVPS points to a potential recalibration of market expectations, improving the valuation balance between market price and underlying equity.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | 2.67 | 102.40 | 26.61 | 6.98 | 3.00 | 57.93 | 7.36 | 5.30 | 4.99 | 1.68 | 4.09 | 7.24 |
| Feb 5, 2024 | 3.96 | 29.97 | 24.94 | 3.35 | 3.47 | 65.80 | 4.01 | 5.48 | 8.68 | 1.75 | 4.57 | 6.26 |
| Feb 6, 2023 | 3.77 | 15.52 | 35.01 | 4.88 | 3.64 | 29.36 | 4.90 | 5.37 | 6.07 | 2.48 | 4.83 | 5.50 |
| Feb 7, 2022 | 3.60 | 16.53 | 18.51 | 4.07 | 4.16 | 25.28 | 3.65 | 5.90 | 5.05 | 3.35 | 5.18 | 6.16 |
| Feb 8, 2021 | 4.81 | 14.18 | 14.53 | 3.55 | 3.93 | 35.07 | 4.33 | 6.72 | 7.46 | 2.98 | 5.15 | 6.30 |
| Feb 7, 2020 | 3.79 | — | 13.84 | 2.80 | 3.72 | 51.67 | 3.93 | 6.61 | 7.83 | 3.00 | 4.16 | 10.23 |
| Feb 7, 2019 | 5.07 | — | 9.41 | 5.89 | 2.80 | 12.87 | 3.89 | 6.08 | 7.79 | 3.80 | 3.75 | 10.68 |
| Feb 8, 2018 | 5.66 | 36.95 | 5.02 | 8.88 | 2.58 | 7.33 | 5.15 | 5.79 | 4.30 | 2.94 | 3.30 | 20.14 |
| Feb 9, 2017 | 8.58 | 21.24 | 4.14 | 5.66 | 2.56 | 6.33 | 4.88 | 4.72 | 4.51 | 3.40 | 2.86 | 18.42 |
| Feb 11, 2016 | 10.53 | 22.17 | 3.94 | 7.04 | 2.53 | 5.51 | 6.59 | 4.07 | 3.15 | 2.84 | 2.42 | 22.38 |
| Feb 12, 2015 | 16.22 | 56.09 | 4.59 | 6.72 | 2.63 | 5.14 | 10.08 | 4.01 | 3.42 | 2.95 | 2.51 | 25.60 |
| Feb 13, 2014 | 16.74 | 18.05 | 4.30 | 5.92 | 2.38 | 3.69 | 11.36 | 3.50 | 3.35 | 2.69 | 2.90 | 14.77 |
| Feb 15, 2013 | 12.91 | 18.06 | 3.57 | 4.40 | 2.23 | 4.15 | 7.01 | 3.29 | 2.44 | 2.42 | 1.72 | 10.08 |
| Feb 21, 2012 | 19.19 | — | 2.83 | 3.50 | 2.17 | 3.35 | 5.08 | 3.13 | 2.14 | 1.95 | 1.38 | 10.05 |
| Feb 17, 2011 | 6.42 | — | 2.04 | 2.76 | 2.39 | 3.21 | 5.29 | 2.88 | 1.85 | 1.75 | 1.41 | 16.16 |
| Feb 18, 2010 | 5.49 | — | 2.46 | 2.88 | 2.07 | 4.17 | 6.74 | 3.45 | 1.97 | 1.57 | 1.29 | 7.45 |
| Feb 26, 2009 | 2.94 | — | 2.48 | 3.29 | 1.69 | 5.01 | 9.83 | 3.56 | 2.72 | 1.44 | 1.02 | 21.09 |
| Feb 27, 2008 | 3.24 | — | 2.77 | 4.22 | 2.62 | 4.16 | 11.76 | 4.17 | 5.38 | 2.32 | 1.62 | 8.92 |
| Mar 12, 2007 | 5.77 | — | 3.96 | 5.50 | 3.32 | 5.43 | 18.07 | 4.78 | 5.45 | 2.49 | 1.38 | 7.52 |
| Feb 28, 2006 | 8.16 | — | 4.26 | 4.00 | 3.78 | 5.85 | 9.18 | 4.66 | 4.30 | 2.94 | 2.03 | 18.12 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 5, 2025 | 2.67 | 7.03 |
| Feb 5, 2024 | 3.96 | 6.77 |
| Feb 6, 2023 | 3.77 | 5.66 |
| Feb 7, 2022 | 3.60 | 5.72 |
| Feb 8, 2021 | 4.81 | 5.99 |
| Feb 7, 2020 | 3.79 | 5.82 |
| Feb 7, 2019 | 5.07 | 6.02 |
| Feb 8, 2018 | 5.66 | 5.14 |
| Feb 9, 2017 | 8.58 | 4.58 |
| Feb 11, 2016 | 10.53 | 4.15 |
| Feb 12, 2015 | 16.22 | 4.47 |
| Feb 13, 2014 | 16.74 | 3.97 |
| Feb 15, 2013 | 12.91 | 3.21 |
| Feb 21, 2012 | 19.19 | 2.55 |
| Feb 17, 2011 | 6.42 | 2.25 |
| Feb 18, 2010 | 5.49 | 2.37 |
| Feb 26, 2009 | 2.94 | 2.60 |
| Feb 27, 2008 | 3.24 | 3.42 |
| Mar 12, 2007 | 5.77 | 3.82 |
| Feb 28, 2006 | 8.16 | 4.00 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 5, 2025 | 2.67 | 5.48 |
| Feb 5, 2024 | 3.96 | 5.44 |
| Feb 6, 2023 | 3.77 | 78,500.89 |
| Feb 7, 2022 | 3.60 | 5.07 |
| Feb 8, 2021 | 4.81 | 4.90 |
| Feb 7, 2020 | 3.79 | 4.71 |
| Feb 7, 2019 | 5.07 | 4.72 |
| Feb 8, 2018 | 5.66 | 4.35 |
| Feb 9, 2017 | 8.58 | 3.91 |
| Feb 11, 2016 | 10.53 | 3.54 |
| Feb 12, 2015 | 16.22 | 4.01 |
| Feb 13, 2014 | 16.74 | 3.40 |
| Feb 15, 2013 | 12.91 | 2.77 |
| Feb 21, 2012 | 19.19 | 2.42 |
| Feb 17, 2011 | 6.42 | 2.15 |
| Feb 18, 2010 | 5.49 | 2.26 |
| Feb 26, 2009 | 2.94 | 2.47 |
| Feb 27, 2008 | 3.24 | 3.28 |
| Mar 12, 2007 | 5.77 | 3.77 |
| Feb 28, 2006 | 8.16 | 3.94 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).